A Naxi ethnic medicine composition with anti-cancer effect and its application

Abstract

The present invention provides a folk prescription with anti-liver cancer and lung cancer effects, its composition and its application, and belongs to the technical field of Naxi ethnic medicine. The main active ingredients of the prescription of the present invention include by mass: 20-40 parts of Paris polyphylla, 5-20 parts of pearl ginseng, 1-10 parts of Panax notoginseng, 1-20 parts of Fritillaria cirrhosa, 1-10 parts of ice balls, 1-10 parts of golden iron locks, 1-10 parts of American ginseng, 1-10 parts of bamboo fungus, 1-10 parts of Qingyang ginseng, 1-20 parts of licorice, and 1-20 parts of Gastrodia elata. The prescription has the characteristics of multi-component-multi-target-multi-pathway anticancer effects tested by network pharmacology, and the ethanol extract of the prescription mainly exerts its effect by inhibiting MAPK and PI3K-Akt signaling pathways. The ethanol extract of the prescription of the present invention and 6 main active compounds have a strong inhibitory effect on cancer cells, showing obvious dose dependence. Moreover, the determination results of 6 core active ingredients are consistent with the research results of network pharmacology. The invention has various raw materials, a scientific and unique formula, is easy to produce and prepare, has significant activity, and can be applied to the treatment of lung cancer and liver cancer.

Description

Technical Field

[0001] The invention belongs to the field of Naxi ethnic medicine, and specifically relates to a Naxi ethnic medicine composition and a traditional Chinese medicine preparation for resisting liver cancer and lung cancer, and applications thereof. Background Art

[0002] As we all know, cancer is the leading cause of death in the world. According to the World Health Organization's 2019 estimate, among 183 countries, cancer ranks first or second in 112 countries and third or fourth in another 23 countries. The top three cancers in terms of incidence are lung cancer, breast cancer, and liver cancer. However, according to the 2020 global cancer statistics, lung cancer is still the leading cause of total cancer deaths, with a mortality rate of about 18%, followed by colorectal cancer (9.4%) and liver cancer (8.3%). There are many ways to treat cancer, including surgery, chemotherapy, radiotherapy, targeted and immunotherapy. However, more and more cancer resistance is caused by chemotherapy and radiotherapy. In addition, chemotherapy and radiotherapy often produce adverse reactions such as mucositis, neurotoxicity and extravasation. Therefore, further research and development of effective anticancer drugs with low toxicity and high efficiency is needed. In order to reduce the adverse reactions of chemotherapy and radiotherapy, traditional Chinese medicine is usually used as an adjuvant therapy. The natural products contained in traditional Chinese medicine can be used to improve the therapeutic effect of chemotherapy, thereby improving the quality of life of patients and prolonging their survival.

[0003] The concept of "network pharmacology" was first proposed by British pharmacologist AL Hopkins. In the present invention, by constructing a "drug-ingredient-target-disease" interaction network, the mechanism of action of traditional Chinese medicine or traditional Chinese medicine prescription is predicted, and the relationship between biological systems and drugs is further revealed, which provides new ideas for the discovery of bioactive substances, mechanism research and new drug development. Traditional Chinese medicine compound is a combination of traditional Chinese medicine produced according to the compatibility principles of traditional Chinese medicine monarch, minister, adjuvant and messenger. The prescription is rigorously matched, which contains rich and complex theoretical inheritance. However, the compatibility rules of traditional Chinese medicine prescriptions are difficult to explain, and its multi-component, multi-target and multi-pathway characteristics are just in line with the research system of network pharmacology. Therefore, the present invention predicts the targets, pathways and active compounds of traditional Chinese medicine compound for the treatment of lung cancer and liver cancer through network pharmacology. Molecular docking is used to evaluate the possibility of interaction between compounds in drugs and human targets, including docking energy and binding form. Finally, in vitro cell experiments are used to further verify the anti-lung cancer and liver cancer effects of the traditional Chinese medicine compound. Summary of the invention

[0004] The first object of the present invention is to provide a prescription and a composition thereof and an ethanol extract thereof having anti-lung cancer and liver cancer effects. The second object of the present invention is to provide a method for preparing the prescription composition. The third object of the present invention is to provide the use of the prescription and the prescription composition and the ethanol extract thereof in the preparation of a drug for treating cancer.

[0005] The present invention provides a prescription with anti-lung cancer and liver cancer effects. The main Chinese medicinal materials include 20-40 parts of Paris polyphylla, 5-20 parts of Panax notoginseng, 1-10 parts of Panax notoginseng, 1-20 parts of Fritillaria cirrhosa, 1-10 parts of Ice ball seeds, 1-10 parts of Gynostemma pentaphyllum, 1-10 parts of American ginseng, 1-10 parts of Bambusa longituba, 1-10 parts of Panax notoginseng, 1-10 parts of Radix Glehniae, 1-10 parts of Radix Glehniae, 1-20 parts of Licorice and 1-20 parts of Gastrodia elata.

[0006] The present invention provides a prescription with anti-lung cancer and liver cancer effects. The main Chinese medicinal materials include 30 parts of Paris polyphylla, 15 parts of Panax notoginseng, 5 parts of Panax notoginseng, 10 parts of Fritillaria cirrhosa, 5 parts of Ice ball seeds, 1 part of Gynostemma pentaphyllum, 5 parts of American ginseng, 1 part of Bambusa longituba, 5 parts of Panax notoginseng, 5 parts of Radix Gastrodiae, 10 parts of Gastrodia elata.

[0007] A traditional Chinese medicine composition for treating liver cancer and lung cancer, comprising: 20 parts of Paris polyphylla, 20 parts of Panax notoginseng, 10 parts of Panax notoginseng, 20 parts of Fritillaria cirrhosa, 10 parts of Ice Ball Seed, 10 parts of Cyathula capitata, 10 parts of American ginseng, 10 parts of Bambusa chinensis, 10 parts of Panax notoginseng, 10 parts of Gastrodia elata, all measured by weight.

[0008] In the prescription and composition of the present invention with anti-lung cancer and liver cancer, Paris polyphylla has the effects of clearing away heat and detoxification, reducing swelling and relieving pain, cooling the liver and calming the nerves; Bamboo fungus has the effect of clearing away heat and detoxification; Pearl ginseng has the effects of nourishing the lung and yin, removing blood stasis and relieving pain; Ice ball has the effects of clearing heat and detoxification, resolving phlegm and dispersing knots; Golden iron lock has the effects of dispelling wind and dampness, dispersing blood stasis and relieving pain, detoxification and reducing swelling. Paris polyphylla, Bamboo fungus, Pearl ginseng, Ice ball, Golden iron lock five kinds of medicine are used together, and the whole prescription has the effects of reducing swelling and relieving pain, clearing away heat and detoxification, removing blood stasis and dispersing knots. All the medicines are used together, and the whole prescription has the effects of invigorating qi and strengthening spleen, clearing away heat and detoxification, and promoting qi and dispersing blood stasis, and can play a blocking effect in the upstream period of cancer treatment.

[0009] Paris polyphylla, bitter, slightly cold, pungent; slightly toxic, enters the liver meridian, has the effects of clearing heat and detoxifying, reducing swelling and dispersing blood stasis, relieving asthma and relieving cough, cooling the liver and calming the nerves. Ginseng, sweet, bitter, warm; enters the liver, lung, and stomach meridians, has the effects of relaxing the meridians and activating collaterals, replenishing blood and stopping bleeding, replenishing the lungs and nourishing yin, removing blood stasis and relieving pain. Panax notoginseng, sweet, slightly bitter, warm; enters the liver and stomach meridians, has the effects of dispersing blood stasis and stopping bleeding, reducing swelling and relieving pain. Fritillaria cirrhosa, bitter, sweet, slightly cold; enters the lung and heart meridians, has the effects of clearing heat and moistening the lungs, resolving phlegm and relieving cough, dispersing nodules and reducing swelling. Ice ball seeds, sweet, slightly pungent, cool; enters the liver and spleen meridians, has the effects of clearing heat and detoxifying, resolving phlegm and dispersing nodules, moistening the lungs and relieving cough. Golden iron lock, pungent, bitter, warm; slightly numb, toxic, enters the liver meridian, has the effects of dispelling wind and dampness, dispersing blood stasis and relieving pain, detoxifying and reducing swelling, promoting blood circulation and expelling parasites. American ginseng tastes sweet, slightly bitter, and cool; it enters the heart, lung, and kidney meridians, and has the effects of replenishing qi and nourishing yin, clearing heat and promoting body fluid. Bamboo mushroom tastes bitter and cold, and has the effects of clearing heat and detoxifying. Green sheep ginseng tastes warm and sweet, and has the effects of removing rheumatism and replenishing deficiency. Licorice tastes sweet, pungent, and flat; it enters the heart, lung, spleen, and stomach meridians, and has the effects of replenishing spleen and qi, clearing heat and detoxifying, removing phlegm and relieving cough, relieving acute pain, and harmonizing various medicines. Gastrodia elata tastes sweet and flat, and enters the liver meridian, and has the effects of calming wind and stopping spasms, calming liver yang, and removing wind and unblocking meridians.

[0010] American ginseng, licorice, and Qingyang ginseng all have the effect of invigorating qi and strengthening the spleen. Paris polyphylla, radix scutellariae, radix scutellariae, licorice, and bamboo fungus all have the effect of clearing away heat and detoxifying. Paris polyphylla, radix scutellariae, Panax notoginseng, Fritillaria cirrhosae, radix scutellariae, radix scutellariae, and Gastrodia elata all have the effect of promoting qi and dispersing blood stasis.

[0011] The raw materials of the prescription of the present invention come from the following sources:

[0012] Paris polyphylla, the dried rhizome of Paris polyphylla var.yunnanensis (Franch.)Hand.-Mazz., a plant of Veratraceae. It is dug up in autumn, the fibrous roots are removed, washed and dried.

[0013] Panax bipinnatifidus Seem. is a dried rhizome of the Araliaceae plant Panax bipinnatifidus Seem. It is harvested in autumn, the rough bark and fibrous roots are removed, and dried; or steamed (boiled) thoroughly and then dried.

[0014] Panax notoginseng, the dried root and rhizome of Panax notoginseng (Burkill) FHChen ex CHChow of the Araliaceae family. Dig it up in autumn before the flowers bloom, wash it, separate the main root, branch root and rhizome, and dry it.

[0015] Fritillaria cirrhosa is the dried bulb of Fritillaria cirrhosa D.Don, a plant of the Liliaceae family. It is dug up in summer and autumn or after the snow melts, and the fibrous roots, rough bark and mud are removed, and then it is sun-dried or dried at low temperature.

[0016] Ice ball seeds are the dried pseudobulbs of Pleione bulbocodioides (Franch.) Rolfe, a plant of the orchid family. They are recorded as "Sancigu" in the "Chinese Pharmacopoeia (2020 Edition)". They are dug up in summer and autumn, the above-ground parts and mud are removed, and the large and small ones are separated and steamed in a boiling water pot until they are thoroughly cooked, and then dried.

[0017] Psammosilene tunicoides is the dried root of Psammosilene tunicoides WCWu & C.Y.Wu, a plant of Caryophyllaceae. It is harvested in autumn, the skin and impurities are removed, and it is dried in the sun. Among the Naxi people, its alias is Dudingzi.

[0018] American ginseng, the dried root of Panax quinquefolius L., a plant of the Araliaceae family. All are cultivated products, dug up in autumn, washed, and dried in the sun or at low temperature.

[0019] Bamboo fungus, the fruiting body of Engleromyces sinensis MAWhalley, Khalil, TZ Wei, YJ Yao & Whalley, a member of the Xylariaceae family. It grows on bamboo poles in subalpine bamboo forests in summer and autumn. It is a parasitic fungus, also known as Chinese fleshy coccus. It can be harvested throughout the year, and after harvesting, it is sliced ​​and dried for later use.

[0020] Qingyang ginseng is the dried root of Cynanchum otophyllum CKSchneid., a plant of Apocynaceae. It is dug up in summer and autumn, and the impurities are removed, the rough skin is scraped off and dried in the sun.

[0021] Yunnan Licorice, the dried root of Glycyrrhiza yunnanensis SH Heng & L.K. Dai ex P.C. Li, a plant of Leguminosae. It is collected in autumn, washed, sliced ​​and sun-dried.

[0022] Gastrodia elata, the dried rhizome of the orchid plant Gastrodia elata Bl., is dug up between the beginning of winter and before Qingming Festival of the following year, immediately washed, steamed, and opened to dry at low temperature.

[0023] The present invention also provides an ethanol extract YF-A for treating liver cancer and lung cancer. The ethanol extract YF-A is obtained by the following preparation method: after the Chinese medicinal materials described in any one of claims 1 to 3 are powdered, they are mixed according to the described ratio, firstly reflux extraction is carried out with 70%-90% ethanol for 2-5 hours, the solid-liquid ratio is 1:2-1:30, the extraction is repeated 2-5 times, each extraction liquid is filtered, the filtrate is enriched, and the solvent is removed by a rotary evaporator to obtain a solvent-free ethanol extract YF-A.

[0024] Furthermore, the implementation methods of the above-mentioned prescription with anti-lung cancer and liver cancer efficacy include but are not limited to: mixing the powders of various Chinese medicines according to a ratio, and giving the patient 3-9g / time, 3 times / day in the form of powder for continuous use for 1-3 months.

[0025] In some embodiments, medically acceptable adjuvants are also included. Specifically, the adjuvants used are pharmaceutical carriers or excipients commonly used in the art, including but not limited to sodium carboxymethyl cellulose, ethyl cellulose, methyl cellulose, gelatin, agar, starch, lactose, glucose, propylene glycol, glycerol, polyethylene glycol, corn syrup, magnesium stearate, stearic acid, compressed tablets, edible flavors and fragrances, etc., to help improve the stability or activity of the drug, or produce an acceptable taste or smell in the case of oral administration.

[0026] In some embodiments, the pharmaceutical composition with anti-lung cancer and liver cancer efficacy is in the form of decoction, tablet, capsule, granule, oral liquid, spray or pill, etc., to facilitate clinical administration.

[0027] When the prescription of the present invention is a decoction, the preparation method thereof comprises the following steps:

[0028] Mix the raw material components according to the proportion, add 8-10 times the water and boil for 30-60 minutes to obtain the product.

[0029] When the prescription of the present invention is a tablet, capsule, granule, oral liquid, spray or pill, etc., the preparation method of the raw material prescription composition comprises the following steps:

[0030] (1) After the medicinal parts of the Chinese medicinal materials are powdered, they are mixed according to the ratio; first, 70%-90% ethanol is used for reflux extraction for 2-5 hours, the solid-liquid ratio is 1:2-1:30, and the extraction is repeated 2-5 times, each extraction liquid is filtered, the filtrate is enriched, and the solvent is removed by a rotary evaporator to obtain a solvent-free prescription ethanol extract (YF-A);

[0031] (2) evaporating the ethanol in the filter residue in (1), refluxing and extracting with distilled water for 2-5 hours, with a solid-liquid ratio of 1:2-1:30, repeating the extraction 2-5 times, filtering each extract, enriching the filtrate, and removing the solvent by rotary evaporation to obtain a solvent-free water extract of the prescription (YF-W);

[0032] (3) Adding conventional excipients for Chinese medicine preparations to the extracts obtained in (1) or / and (2) above, and preparing the extracts according to conventional preparation steps for Chinese medicine preparations to prepare tablets, capsules, granules, oral liquids, sprays or pills.

[0033] The third object of the present invention is to provide the use of the prescription, the prescription composition and the ethanol extract of the prescription in the preparation of a drug for treating cancer. Specifically, the cancer is any one or more of lung cancer, liver cancer and the like. Provided is a Chinese medicine composition for treating liver cancer or lung cancer as described in any of the above, or an ethanol extract of the Chinese medicine composition, or the use of any of the Chinese medicine preparations as described in any of the above in the preparation of a drug for treating lung cancer or liver cancer.

[0034] Compared with the prior art, the prescription with anti-liver cancer and lung cancer effect, the ethanol extract thereof and the Chinese medicine composition thereof of the present invention have the following advantages:

[0035] (1) Cell experiments show that the prescription with anti-cancer efficacy and its ethanol extract and its Chinese medicine composition can significantly inhibit the vitality of cancer cells (lung cancer cells A549, lung cancer cells NCI-H1581, liver cancer cells HepG2), and its composition and its ethanol extract can induce apoptosis of liver cancer cells HepG2, and show concentration dependence; in addition, the composition and its ethanol extract can induce liver cancer cells HepG2 to undergo cycle arrest at the G2 / M phase, and show concentration dependence. The composition and its ethanol extract can further reduce the mitochondrial membrane potential of liver cancer cells HepG2 as the concentration increases, further indicating that the prescription with anti-cancer efficacy and its ethanol extract and its composition can make the apoptosis of liver cancer cells HepG2 irreversible. This shows that the prescription with anti-cancer efficacy and its ethanol extract and its composition can play a blocking effect in the early stage of anti-cancer treatment, effectively prevent and treat cancer cell proliferation, and further play a role in the treatment and adjuvant treatment of cancer.

[0036] (2) Network pharmacology analysis shows that the prescription with anti-cancer efficacy, its ethanol extract and its Chinese medicine composition can play an interventional therapeutic role on multiple pathways and multiple targets of cancer occurrence and development. Molecular docking analysis is used to evaluate the possibility of interaction between the active compounds in the prescription and the targets, further verifying that the prescription with anti-cancer efficacy, its composition and its ethanol extract of the present invention have anti-cancer efficacy.

[0037] (3) The prescription with anti-cancer efficacy and its ethanol extract and its Chinese medicine composition described in the present invention have the effects of invigorating qi and strengthening the spleen, clearing away heat and detoxifying, and promoting qi and dispersing blood stasis. They are mainly used for treating and assisting the unlimited proliferation of cancer cells caused by liver cancer and lung cancer, and further promoting the apoptosis of cancer cells, thereby playing the role of treating and assisting the treatment of cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 It is the network diagram of “TCM-compound-target” in the prescription;

[0039] Figure 2 It is a Venn diagram of the intersection of the main active ingredients in the prescription and the target protein of the disease;

[0040] Figure 3 is the protein network interaction diagram;

[0041] Figure 4 It is the interaction network diagram of main active compounds, traditional Chinese medicine and key targets of prescriptions;

[0042] Figure 5 It is a biological function and pathway analysis diagram;

[0043] Figure 6 It is the “compound-target-pathway” interaction network diagram of the prescription;

[0044] Figure 7 It is a 3D visualization diagram of the docking of the core target and the corresponding active compound molecule;

[0045] Figure 8 The inhibitory effects of YF-A (A) and DOX (B) on liver cancer cells;

[0046] Fig. 9 It is the effect of the prescription on the cycle and apoptosis of liver cancer cells;

[0047] Fig.10 It is the effect of the prescription on the mitochondrial membrane potential of liver cancer cells. DETAILED DESCRIPTION

[0048] The present invention will be further described below with reference to specific embodiments in conjunction with the accompanying drawings. It should be understood that the embodiments described herein are only used to explain the present invention and are not used to limit the technical solutions of the present invention.

[0049] If no specific conditions are specified in the examples, the experiments were carried out under conventional conditions or conditions recommended by the manufacturer. If no manufacturer is specified for the instruments or reagents used, they are all conventional products available on the market.

[0050] Example 1

[0051] The present invention provides a prescription and a composition for preventing lung cancer and liver cancer, and the preparation method thereof comprises the following steps:

[0052] (1) Powdering the medicinal parts of the Chinese medicinal materials of the present invention (in parts by weight, including 20-40 parts of Paris polyphylla, 5-20 parts of Glehnia littoralis, 1-10 parts of Panax notoginseng, 1-20 parts of Fritillaria cirrhosa, 1-10 parts of Psoralea corylifolia, 1-10 parts of Gastrodia elata, 1-10 parts of Cyathula capitata, 1-10 parts of American ginseng, 1-10 parts of Bamboo fungus, 1-10 parts of Panax notoginseng, 1-20 parts of Licorice, and 1-20 parts of Gastrodia elata) and mixing them according to the ratio; firstly reflux extraction with 70%-90% ethanol for 2-5 hours, with a solid-liquid ratio of 1:2-1:30, repeating the extraction 2-5 times, filtering the extract each time, enriching the filtrate, removing the solvent by rotary evaporator, and obtaining a solvent-free ethanol extract (YF-A);

[0053] (2) The ethanol in the filter residue in (1) is evaporated, and the mixture is extracted with distilled water under reflux for 2-5 hours at a solid-liquid ratio of 1:2-1:30. The extraction is repeated 2-5 times, and the extract is filtered each time to enrich the filtrate. The solvent is removed by a rotary evaporator to obtain a solvent-free water extract (YF-W).

[0054] Example 2

[0055] The medicinal decoction with anti-cancer efficacy of this embodiment is prepared from the following components: 30g of Paris polyphylla, 15g of Glehnia littoralis, 5g of Panax notoginseng, 10g of Fritillaria cirrhosa, 5g of Ice Ball Seed, 1g of Gynostemma pentaphyllum, 5g of American ginseng, 1g of Bamboo Fungus, 5g of Panax notoginseng, 5g of Licorice, and 10g of Gastrodia elata.

[0056] Or, Paris polyphylla 30g, Glossy ginseng 15g, Panax notoginseng 5g, Fritillaria cirrhosa 20g, Ice ball seed 10g, Gynostemma pentaphyllum 10g, American ginseng 10g, Bambusa tenuifolia 1g, Panax notoginseng 5g, Licorice root 20g, Gastrodia elata 20g.

[0057] Or, Paris polyphylla 20g, Panax notoginseng 5g, Panax notoginseng 10g, Fritillaria cirrhosa 10g, Ice ball seed 5g, Gynostemma pentaphyllum 5g, American ginseng 5g, Bambusa tenuifolia 2g, Panax notoginseng 5g, Licorice root 20g, Gastrodia elata 20g.

[0058] Or, Paris polyphylla 40g, Panax notoginseng 20g, Panax notoginseng 10g, Fritillaria cirrhosa 10g, Ice ball seed 5g, Gynostemma pentaphyllum 8g, American ginseng 5g, Bambusa tenuifolia 5g, Panax notoginseng 10g, Licorice root 15g, Gastrodia elata 15g.

[0059] Or, Paris polyphylla 40g, Glossy ginseng 20g, Panax notoginseng 10g, Fritillaria cirrhosa 20g, Ice ball seed 10g, Gynostemma pentaphyllum 10g, American ginseng 10g, Bambusa tenuifolia 10g, Panax notoginseng 10g, Licorice root 20g, Gastrodia elata 20g.

[0060] The preparation method is as follows: various raw material components are mixed according to a proportion, and water of about 10 times the weight is added and boiled for 40 minutes to obtain the product.

[0061] Example 3

[0062] The prescription with anti-cancer efficacy and the tablets of the composition thereof of this embodiment are prepared from the following components: 30g of Paris polyphylla, 15g of Glehnia littoralis, 5g of Panax notoginseng, 10g of Fritillaria cirrhosa, 5g of Ice ball seeds, 1g of Gastrodia elata, 5g of American ginseng, 1g of Bamboo mushroom, 5g of Panax notoginseng, 5g of Licorice root, and 10g of Gastrodia elata.

[0063] Or, Paris polyphylla 40g, Glossy ginseng 15g, Panax notoginseng 5g, Fritillaria cirrhosa 20g, Ice ball seed 10g, Gynostemma pentaphyllum 10g, American ginseng 10g, Bambusa tenuifolia 1g, Panax notoginseng 5g, Licorice root 20g, Gastrodia elata 20g.

[0064] Or, Paris polyphylla 20g, Panax notoginseng 5g, Panax notoginseng 10g, Fritillaria cirrhosa 10g, Ice ball seed 5g, Gynostemma pentaphyllum 5g, American ginseng 5g, Bambusa striatum 4g, Panax notoginseng 5g, Licorice root 20g, Gastrodia elata 20g.

[0065] Or, Paris polyphylla 40g, Panax notoginseng 20g, Panax notoginseng 10g, Fritillaria cirrhosa 10g, Ice ball seed 5g, Gynostemma pentaphyllum 6g, American ginseng 5g, Bambusa tenuifolia 10g, Panax notoginseng 10g, Licorice root 15g, Gastrodia elata 15g.

[0066] The preparation method is as follows: the raw material components are mixed according to the proportion, 75% ethanol of about 10 times the weight is added for reflux extraction for 3 hours, the extraction is repeated 3 times, each extraction liquid is filtered, the filtrate is enriched, the solvent is removed by a rotary evaporator, and the solvent-free ethanol extract (YF-A) is obtained. Excipients and auxiliary materials are added, and tablets are prepared according to the conventional tablet process of traditional Chinese medicine.

[0067] Example 4

[0068] The anti-cancer prescription of this embodiment and the capsule, granule, oral liquid, spray or pill of the composition thereof.

[0069] It is prepared from the following components: 30g of Paris polyphylla, 15g of Panax notoginseng, 5g of Panax notoginseng, 10g of Fritillaria cirrhosa, 5g of Ice Ball Seed, 1g of Gynostemma pentaphyllum, 5g of American ginseng, 1g of Bamboo Fungus, 5g of Panax notoginseng, 5g of Licorice, and 10g of Gastrodia elata.

[0070] Or, Paris polyphylla 40g, Glossy ginseng 15g, Panax notoginseng 5g, Fritillaria cirrhosa 20g, Ice ball seed 10g, Gynostemma pentaphyllum 10g, American ginseng 10g, Bambusa tenuifolia 1g, Panax notoginseng 5g, Licorice root 20g, Gastrodia elata 20g.

[0071] Or, Paris polyphylla 20g, Panax notoginseng 5g, Panax notoginseng 10g, Fritillaria cirrhosa 10g, Ice ball seed 5g, Gynostemma pentaphyllum 5g, American ginseng 5g, Bambusa tenuifolia 5g, Panax notoginseng 5g, Licorice root 20g, Gastrodia elata 20g.

[0072] Or, Paris polyphylla 40g, Panax notoginseng 20g, Panax notoginseng 10g, Fritillaria cirrhosa 10g, Ice ball seed 5g, Gynostemma pentaphyllum 3g, American ginseng 5g, Bambusa tenuifolia 10g, Panax notoginseng 10g, Licorice root 15g, Gastrodia elata 15g.

[0073] The preparation method is as follows: the raw material components are mixed according to a ratio, 75% ethanol of about 10 times the weight is added for reflux extraction for 3 hours, the extraction is repeated 3 times, each extraction liquid is filtered, the filtrate is enriched, and the solvent is removed by a rotary evaporator to obtain a solvent-free prescription ethanol extract (YF-A). The ethanol extract (YF-A) of the prescription is taken and prepared into capsules, granules, oral liquids, sprays or pills according to the conventional preparation method of Chinese medicine capsules, granules, oral liquids, sprays or pills.

[0074] Example 5

[0075] The pharmacological effects of the anti-cancer prescription and its composition described in the present invention on the treatment of liver cancer and lung cancer are further illustrated below through network pharmacology, molecular docking and cell experiments.

[0076] 1. A method for analyzing the anticancer effects of active ingredients in prescriptions based on network pharmacology and molecular docking.

[0077] 1. Methods and steps.

[0078] 1.1 Collection of active ingredients in prescriptions and their targets.

[0079] The active compounds of each Chinese medicine were collected through the TCMSP database (Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, https: / / tcmspw.com / tcmsp.php), the BATMAN-TCM database (Bioinformatics Analysis Tool for Molecular mechanism of Traditional Chinese Medicine, http: / / bionet.ncpsb.org.cn / batman-ttc / ) and literature (CNKI, Web of Science). In TCMSP, the ADME attribute values ​​were set as oral bioavailability (OB) ≥ 30% and drug similarity (DL) ≥ 0.18. In BATMAN-TCM, the threshold (Score cutoff> 20) and P < 0.05 were set. Finally, the qualified active compounds of the prescription and their targeted genes were obtained, and all gene names were corrected by the UniProt database (https: / / www.uniprot.org / ).

[0080] 1.2 Collection of disease targets.

[0081] Disease targets related to liver cancer and lung cancer were collected through the GeneCards database (https: / / www.genecards.org / ), the OMIM database (Online Mendelian Inheritance in Man, https: / / omim.org / ), the TTD database (Therapeutic Target, http: / / db.idrblab.net / ttd / ), and the DrugBank database (https: / / go.drugbank.com / ). The duplicate regions of the gene targets were removed, and the results of the disease targets in the four databases were visualized using a Venn diagram. All disease targets were corrected using the UniProt database. The Venny software was used to intersect the targets corresponding to the active ingredients and the disease targets, and the intersecting targets were the anticancer treatment targets of the prescription.

[0082] 1.3 Construction of the “drug-ingredient-target-disease” interaction network.

[0083] The anticancer therapeutic targets of the prescription were entered into the String database (https: / / string-db.org / ), and the protein-protein interaction (PPI) network was constructed using Cytoscape 3.7.1 software. The topological parameters of all nodes in the network diagram were calculated at the same time, and the node screening conditions were determined: degree, betweenness and other parameters were selected as the screening conditions for core nodes, and the top 20 anticancer targets and core active ingredients in the prescription were selected to construct a "drug-ingredient-target-disease" interaction network diagram.

[0084] 1.4GO and KEGG pathway enrichment analysis.

[0085] The core targets were analyzed by GO functional analysis and KEGG pathway analysis using the Metascape database (https: / / metascape.org), with the species set to "Homo Sapiens" and the P value cutoff value of 0.01. The top 20 GO biological processes and KEGG signaling pathways were selected based on the P value and visualized.

[0086] 1.5 Molecular docking analysis.

[0087] First, the 2D structure of the main active ingredient (ligand) of the prescription for cancer treatment was downloaded from the PubChem (https: / / pubchem.ncbi.nIm.nih.gov / ) website, and the 3D structure of the small molecule ligand was drawn using the Chemoffice software. Secondly, the protein name corresponding to the core gene was found using the Uniprot (https: / / www.uniprot.org / ) website, and the protein name was used to find the three-dimensional structure of the protein receptor of the gene from the PDB protein database (http: / / www.rcsb.org / ). Finally, the Autodock software was used to calculate and obtain the binding energy and binding site of the protein receptor and the small molecule ligand, and the docking results were visualized and analyzed using the PyMOL software, and finally the molecular docking conformation was obtained.

[0088] 2. Results.

[0089] 2.1 Information on the main active ingredients and potential targets of the prescription.

[0090] Through the TCMSP database, BATMAN-TCM database and literature, the main active ingredients of 176 prescriptions were obtained. In terms of the active ingredients contained in a single drug, there are 5 Paris polyphylla (CL), 3 Panax notoginseng (ZZS), 41 Panax notoginseng (SQ), 19 Fritillaria cirrhosa (CBM), 7 Ice ball seeds (DSL), 1 Jissa sutchuenensis (JTS), 40 American ginseng (XYS), 12 bamboo fungus (ZJ), 9 Panax notoginseng (QYS), 39 Glycyrrhiza uralensis (GC), and 14 Gastrodia elata (TM). At the same time, the present invention also obtained a total of 1133 potential gene targets corresponding to these 176 main active compounds. The traditional Chinese medicine-compound-target network diagram was constructed using Cytoscape software, with a total of 1314 nodes and 4284 edges, as shown in Figure 2. Figure 1 shown.

[0091] 2.2 Disease target screening and component-disease target cross-collection.

[0092] Using "liver cancer" and "lung cancer" as keywords, we searched for disease targets from GeneCards, OMIM, TTD, and DrugBank databases. After merging the data from the four databases and deleting duplicate data, we screened out 4,928 liver cancer disease targets and 6,352 lung cancer disease targets, respectively. Then, we drew the combined targets of prescriptions and diseases through Venn diagrams, and obtained 583 intersection targets between liver cancer and prescriptions, and 658 intersection targets between lung cancer and prescriptions.

[0093] 2.3 Construction and analysis of the prescription “drug-ingredient-target-disease” network.

[0094] The cross-targets of cancer treatment through prescriptions were obtained from the String database and Cytoscape software to obtain the “drug-ingredient-target-disease” network diagram, which contains 880 nodes and 21,023 edges, such as Figure 2 As shown. Key targets were collected according to degree sorting. The larger the degree, the darker the color and the larger the node shape. The average node degree was 47.780, and the average local clustering coefficient was 0.425. The network analysis was performed using Cytoscape software. The top 20 targets by degree are shown in Table 1, which are mainly related to liver cancer apoptosis.

[0095] Table 1 Names of the top 20 targets by degree

[0096]

[0097] The interaction diagrams of the top 20 key targets and the anticancer active ingredients of the prescription were obtained by Cytoscape software, such as Figure 4 As shown in Table 2. Node size and color depth indicate degree. The larger the node, the darker the color and the larger the degree value. Among them, red represents 11 kinds of traditional Chinese medicine; green represents the top 20 anticancer targets in the prescription degree; purple CF1, CF2, CF3 and CF10 represent 4 repeated compounds in the 11 kinds of traditional Chinese medicine; orange represents the top 35 compounds found in the prescription ranked by degree value, as shown in Table 2.

[0098] Table 2 Top 35 active ingredients in prescriptions

[0099]

[0100] 2.4 Biological function and pathway analysis.

[0101] The GO and KEGG enrichment analysis of the top 20 anti-cancer targets of the prescription was performed using the Metscape database. The results are as follows Figure 5 As shown in Figure 2, GO enrichment analysis results showed that 771 biological processes (biological process, BP, Figure 5 Middle A), 39 cellular components (cellular component, CC, Figure 5 Middle B), 45 molecular function (molecular function, MF, Figure 5 Middle C). There are 128 pathways in KEGG enrichment analysis ( Figure 5 D, Table 3). The top 20 data of BP, CC, MF, and GO were analyzed and visualized according to the p-value ( Figure 5 , Table 3). Figure 5In the figure, the size of the dots indicates the number of enriched targets. The larger the dots, the more enriched targets. In addition, the significance of enrichment can be predicted by the color depth of the dots. The redder the color of the dots, the smaller the p-value, and the greater the significance of enrichment.

[0102] From the enrichment results, BP mainly includes positive regulation of epithelial cell proliferation, positive regulation of transferase activity, and positive regulation of gland development. These positive regulations are closely related to the regulation of cell apoptosis, proliferation, phosphorylation, enzyme activity, DNA, miRNA metabolism and transcription process ( Figure 5 (A). CC mainly involves transcriptional regulatory complexes, transcriptional repression complexes, membrane rafts, membrane microdomains and euchromatin ( Figure 5 (B). The changes in MF are mainly reflected in DNA binding, transcription factor binding, kinase binding, transcription factor binding, transcription factor binding, and nitric oxide synthase regulator activity ( Figure 5 C). The signal pathway enrichment results of the Metascape database showed that there were 4 signal pathways: PI3K-Akt, MAPK, thyroid hormone and AGE-RAGE; there were 6 cancer-related signal pathways: including cancer, breast cancer, colorectal cancer, prostate cancer, endometrial cancer, and bladder cancer; 3 related viral infection pathways included human cytomegalovirus infection, Kaposi's sarcoma-associated herpes virus infection, and human papillomavirus infection. However, the KEGG enrichment pathway results showed that the prescription was directly related to hepatitis C and hepatitis B ( Figure 5 D, Table 3). In summary, based on the above results, the anticancer process of the prescription may involve multiple pathways, multiple targets, multiple biological processes, multiple molecular functions and cellular components.

[0103] Furthermore, a “compound-target-pathway” diagram was constructed using Cytoscape software ( Figure 6 ), visual analysis of interactions between active ingredients, top 20 potential targets, and pathways. Figure 6 It contains 75 nodes and 294 edges, among which green nodes represent the top 20 hub genes, blue nodes represent pathways related to the target, and orange nodes represent active compounds related to the target. The larger the node shape, the darker the color, and the greater the degree value. The results of network diagram analysis show that there are complex correlations between different compounds, targets, and pathways. Among them, the network diagrams of "single target-multiple pathways", "single pathway-multiple targets", "single target-multiple compounds", and "single compound-multiple targets" have clear visual relationships.

[0104] Table 3 Top 20 KEGG signaling pathways

[0105]

[0106] 2.5 Analysis of molecular docking results.

[0107] Small molecule active ingredients in drug prescriptions are usually called ligands, while target proteins in the human body are usually called receptors. Molecular docking is used to evaluate the possibility of interaction between ligands and receptors. Generally speaking, whether a ligand can bind to a receptor is mainly evaluated by binding energy. If the binding energy is less than 0, it indicates that the ligand and receptor can bind spontaneously.

[0108] The present invention selected three core proteins with high affinity against liver cancer, namely EGFR, TP53 and AKT1, and carried out molecular docking with 32 active compounds. These three targets are all related to the signaling pathways of cancer, MAPK, PI3K-Akt and hepatitis B. Both TP53 and AKT1 targets are related to the signaling pathway of hepatitis C. The binding energy results are shown in Tables 4, 5 and 6. The results showed that the 32 active ingredients BWY have strong binding ability with the three core target proteins. Among them, the binding abilities of three compounds (CBM16, CBM9 and ZJ2) with the three targets (EGFR, TP53 and AKT1) ranked in the top five respectively. All of them are located in the active pockets of the targets, and most of them are bound by hydrogen bonds. The molecular docking results of the three active compounds with the three core targets were visualized using PyMol software, as shown in the figure. Figure 7 shown.

[0109] Table 4 Molecular docking energy of target EGFR

[0110]

[0111] Table 5 Molecular docking energy of target TP53

[0112]

[0113]

[0114] Table 6 Molecular docking energy of target AKT1

[0115]

[0116]

[0117] In summary, after performing network pharmacology analysis on the composition of the prescription of the present invention, it was found that it can play an interventional therapeutic role on multiple pathways and multiple targets of cancer occurrence.

[0118] 2. Analyze the anti-cancer efficacy of the prescription based on cell experiments.

[0119] 1Methods and steps.

[0120] 1.1 Evaluation of cell proliferation activity of prescription extracts.

[0121] The Cell Counting Kit (CCK-8) method was used to evaluate the inhibitory activity of the prescription on cell proliferation, and the half-maximal inhibitory concentration IC50 value was determined by single-concentration activity screening and multiple-concentration determination.

[0122] The experimental steps are as follows:

[0123] (1) Inoculation of cells: Prepare a single cell suspension of cells using culture medium containing 10% fetal bovine serum, and inoculate 90 μL of 5×10 cells per well of a 96-well plate. 4 / mL of adherent cells and 9×10 4 / mL of suspension cells were pre-cultured at 5% CO2 and 37°C for 24h.

[0124] (2) Add the sample solution to be tested: add 10 μL of sample solution to each well. For the initial screening of activity, set one concentration for each sample and set three replicate wells; for IC50 determination, set eight concentrations and set three replicate wells for each concentration; place in an incubator and culture for 48 hours. The experiment sets up a blank group (Blank), a control group (Control), and a drug group (Drug).

[0125] (3) Color development: Aspirate the old culture medium and drug solution from adherent cells (add 10 μL CCK-8 stock solution directly to suspended cells), add 100 μL CCK-8 solution diluted ten times to each well, and continue culturing at 37°C, 5% CO2 for 1-4 h (keep away from light and observe in real time).

[0126] (4) Detection: Measure the absorbance at 450 nm using an enzyme-labeled instrument and record the raw data results.

[0127] (5) The original data were standardized using Excel software, and the cell proliferation inhibition rate was calculated by the OD value of each well in the initial screening (formula = (OD Control -OD Drug ) / (OD Control -OD Blank )×100%), and the inhibition rate was statistically analyzed. IC50 was calculated by GraphPadPrism 8 (version 8.0.2, GraphPad Software Inc), and the experimental results were expressed as ±SD.

[0128] (6) The positive control was doxorubicin hydrochloride (Dox).

[0129] 1.2 Effects of medicinal extracts on the cell cycle and apoptosis of liver cancer cells.

[0130] The cell cycle and apoptosis detection kit (Biyuntian, product number C1052) was used to detect the effect of the prescription on the cell cycle and apoptosis of liver cancer cells.

[0131] The experimental steps are as follows:

[0132] (1) Take out the HepG2 cell culture dish from the 37°C 5% CO2 incubator, digest with trypsin, and repeatedly pipette and transfer the cell suspension into a 15 mL centrifuge tube.

[0133] (2) The cells counted were divided into 10 6 / well, inoculated in a 6-well white transparent bottom cell plate, 2 mL / well; 3 replicates were made for each experimental group. The cell plate was placed in a 37°C, 5% CO2 incubator for incubation.

[0134] (3) After adhesion, the culture medium in the wells was discarded and 2 mL of serum-free culture medium was added to each well for starvation treatment for 24 h.

[0135] (4) After starvation, the liquid in the wells was discarded, and the cell culture plates were administered drugs according to the drug concentrations required by the experiment (three concentrations, namely: 0.125, 0.25, and 1 mg / mL, one control group, and one positive control drug DOX, with 6 replicate wells in each group), and placed in a 37°C, 5% CO2 incubator for 24 h.

[0136] (5) Aspirate the cell culture medium into a suitable centrifuge tube, wash the adherent cells once with PBS, and add an appropriate amount of trypsin cell digestion solution (without EDTA) to digest the cells. Incubate at room temperature until the adherent cells can be blown off by gently blowing, and then aspirate the trypsin cell digestion solution. Avoid excessive digestion with trypsin.

[0137] (6) Add the cell culture medium collected in step (5), gently blow down the cells, transfer them to a centrifuge tube, centrifuge at 1000g for 5 minutes, discard the supernatant, collect the cells, gently resuspend the cells with PBS and count them.

[0138] (7) Flow cytometry detection of cell cycle:

[0139] I. Take 100,000-1,000,000 resuspended cells, centrifuge at 1000 g for 5 minutes, and discard the supernatant;

[0140] II. Fix the cells: Add 1 mL of ice-cold 70% ethanol, gently blow and mix, and fix at 4℃ for 2 hours. Centrifuge at about 1000g for 5 minutes to precipitate the cells. Add about 1 mL of ice-cold PBS to resuspend the cells. Centrifuge again to precipitate the cells and carefully remove the supernatant.

[0141] III. Staining: Add 0.5 mL of propidium iodide staining solution to each tube of cell sample, slowly and fully resuspend the cell pellet, and incubate at 37°C in the dark for 30 minutes. Then store in an ice bath in the dark.

[0142] IV. Flow cytometric detection and analysis: Flow cytometry was used to detect red fluorescence at an excitation wavelength of 488 nm and light scattering at the same time. Flow analysis software was used to analyze cell DNA content and light scattering. 10,000 cells were counted in each group.

[0143] (8) Flow cytometry detection of cell apoptosis:

[0144] I. Take 50,000-100,000 resuspended cells, centrifuge at 1000g for 5 minutes, discard the supernatant, add 195μL Annexin V-FITC binding solution and gently resuspend the cells.

[0145] II. Add 5 μL Annexin V-FITC and mix gently.

[0146] III. Add 10 μL of propidium iodide staining solution and mix gently.

[0147] IV. Incubate at room temperature in the dark for 20 minutes, then place in an ice bath. Flow cytometry detection: Annexin V-FITC is green fluorescence, and propidium iodide (PI) is red fluorescence. 10,000 cells are counted in each group.

[0148] 1.3 Effect of medicinal extracts on mitochondrial membrane potential of liver cancer cells.

[0149] The mitochondrial membrane potential detection kit (JC-1, Bio-Tech, catalog number C2006) was used to detect the effect of the prescription on the mitochondrial membrane potential of liver cancer cells.

[0150] The experimental steps are as follows:

[0151] (1) Preheat the culture medium used in the cell subculture process in a 37°C water bath.

[0152] (2) Take out the HepG2 cell culture dish from the 37°C 5% CO2 incubator, digest with trypsin, and repeatedly pipette and transfer the cell suspension into a 15 mL centrifuge tube.

[0153] (3) The cells counted were divided into 10 5 / well, inoculated in a 24-well white transparent bottom cell plate, 500 μL / well; three replicates were made for each experimental group. The cell plate was placed in a 37°C, 5% CO2 incubator for incubation.

[0154] (4) After adhesion, the culture medium in the wells was discarded and 500 μL of serum-free culture medium was added to each well for starvation treatment for 24 h.

[0155] (5) After starvation, the liquid in the wells was discarded, and the cell culture plates were administered drugs according to the drug concentrations required by the experiment (three concentrations, namely: 0.125, 0.25, and 0.5 mg / mL, one control group, and one positive control drug DOX, with three replicate wells in each group), and placed in a 37°C, 5% CO2 incubator for 24 h.

[0156] (6) After the incubation is completed, discard the supernatant and add JC-1 staining solution according to the instructions of the Mitochondrial Membrane Potential Assay Kit (JC-1). Incubate at 37°C for about 20 minutes. After the incubation is completed, remove the supernatant and wash twice with JC-1 staining buffer (1X).

[0157] (7) Add 500 μL of cell culture medium and observe under an inverted fluorescence microscope.

[0158] (8) When detecting JC-1 monomer, the excitation light was set to 490 nm and the emission light was set to 530 nm; when detecting JC-1 polymer, the excitation light was set to 525 nm and the emission light was set to 590 nm.

[0159] 2Results.

[0160] 2.1 Evaluation results of cell proliferation activity of the Chinese herbal extracts (YF-W) and (YF-A) of the present invention.

[0161] The CCK-8 method was used to evaluate the cell proliferation activity of the extracts of the prescription at different concentrations. The results showed that compared with the positive control group, YF-A significantly inhibited the growth of tumor cells in a dose-dependent manner ( Figure 8 ). To obtain the optimal inhibitory concentration, the IC50 values ​​were calculated, see Table 7. The IC50 values ​​of YF-A against A549 human non-small cell lung cancer cells, NCI-H1581 human non-small cell lung cancer cells, and HepG2 human liver cancer cells were 0.3833 mg / mL, 0.7682 mg / mL, and 0.2509 mg / mL, respectively, and the YF-W part was inactive. These results indicate that the ethanol extract of the prescription inhibits the cell proliferation of lung cancer cell lines by inhibiting the MAPK and PI3K-Akt signaling pathways. The inhibitory effects of YF-A and DOX on liver cancer cells (HepG2) are shown in Figure 7. Figure 8 As shown, the results showed that YF-A had a significant inhibitory effect on liver cancer cells (HepG2) in a concentration-dependent manner.

[0162] Combined with the previous network pharmacology and molecular docking results, the present invention uses 6 main active compounds (CBM9-Verticinone, CBM16-Solanidine, SQ7-Quercetin, CF3-Ginsenoside Rh2, CL2-Diosgenin, CL3-Pennogenin) to further test its inhibitory effect on liver cancer cells (HepG2). The results are shown in Table 8. The 6 core active compounds all showed obvious inhibitory effects on HepG2 cell lines, and had obvious dose dependence. The results showed that the determination results of these 6 central active components were consistent with the predictions of network pharmacology.

[0163] Table 7 IC50 values ​​of the Chinese herbal extracts (YF-W) and (YF-A) of the present invention on liver cancer and lung cancer cells

[0164]

[0165] Table 8 IC50 values ​​of 6 active compounds against liver cancer cells

[0166]

[0167] 2.2 The effects of the Chinese herbal extract YF-A of the present invention on the cell cycle and apoptosis of liver cancer cells.

[0168] PI staining and flow cytometry were used to detect the effects of the prescription on the cell cycle and apoptosis of liver cancer cells. Fig. 9 As shown. The cell cycle results showed that YF-A could induce cell cycle arrest in the G2 / M phase of liver cancer HepG2 cells, and it was concentration-dependent. The apoptosis results showed that YF-A could induce apoptosis in liver cancer HepG2 cells, and it was concentration-dependent.

[0169] 2.3 The results of the effect of the Chinese herbal extract YF-A of the present invention on the mitochondrial membrane potential of liver cancer cells.

[0170] The mitochondrial membrane potential detection kit (JC-1) and an inverted fluorescence microscope (Olympus, IX70) were used to detect the effect of the prescription on the mitochondrial membrane potential of liver cancer cells. Fig.10 The cell cycle results show that the Chinese herbal extract YF-A of the present invention can reduce the mitochondrial membrane potential of liver cancer HepG2 cells, and as the drug concentration increases, the mitochondrial membrane potential tends to decrease.

[0171] In summary, the main core compounds, targets and pathways of the prescription in the treatment of cancer were predicted by network pharmacology, and the molecular docking experiment further verified that the prescription treated cancer (mainly lung cancer and liver cancer) through multi-target-multi-pathway-multi-component. Further, through a series of experiments such as cell proliferation activity, cell cycle, cell apoptosis, mitochondrial membrane potential, it was found that the Chinese medicine extract YF-A of the present invention has the effect of promoting cancer cell apoptosis. The results show that the Chinese medicine extract YF-A of the present invention has anti-cancer efficacy.

[0172] Various embodiments of the present invention have been described above. The above description is exemplary, not exhaustive, and is not limited to the various embodiments described.

Claims

1. A Chinese medicine composition for treating liver cancer and lung cancer, characterized in that: The Chinese medicine composition is prepared from the following components: 20-40 parts of Paris polyphylla, 5-20 parts of Panax notoginseng, 1-10 parts of Panax notoginseng, 1-20 parts of Fritillaria cirrhosa, 1-10 parts of Psoralea corylifolia, 1-10 parts of Cyperus rotundus, 1-10 parts of American ginseng, 1-10 parts of Bamboo fungus, 1-10 parts of Panax notoginseng, 1-20 parts of Gastrodia elata, all in parts by weight. The preparation method of the Chinese medicine composition comprises the following steps: after the above-mentioned Chinese medicinal materials are powdered, they are mixed according to the above-mentioned ratio, firstly reflux extraction is performed with 70%-90% ethanol for 2-5 hours, the material-liquid ratio is 1:2-1:30, the extraction is repeated 2-5 times, each extraction liquid is filtered, the filtrate is enriched, and the solvent is removed by a rotary evaporator.

2. A Chinese medicine composition for treating liver cancer and lung cancer according to claim 1, characterized in that: The invention is prepared from the following components: 30 parts of Paris polyphylla, 15 parts of Panax notoginseng, 5 parts of Panax notoginseng, 10 parts of Fritillaria cirrhosa, 5 parts of Ice ball seeds, 1 part of Gynostemma pentaphyllum, 5 parts of American ginseng, 1 part of Bambusa longituba, 5 parts of Panax notoginseng, 5 parts of Gastrodia elata, all of which are calculated by weight.

3. A Chinese medicine composition for treating liver cancer and lung cancer according to claim 1, characterized in that: The invention is prepared from the following components: 20 parts of Paris polyphylla, 20 parts of Panax notoginseng, 10 parts of Panax notoginseng, 20 parts of Fritillaria cirrhosa, 10 parts of Ice ball seeds, 10 parts of Gynostemma pentaphyllum, 10 parts of American ginseng, 10 parts of Bambusa chinensis, 10 parts of Panax notoginseng, 10 parts of Radix Glycyrrhizae, 20 parts of Licorice and 20 parts of Gastrodia elata, all of which are calculated by weight.

4. An ethanol extract YF-A for treating liver cancer and lung cancer, characterized in that: The ethanol extract YF-A is obtained by the following preparation method: after the Chinese medicinal materials described in any one of claims 1 to 3 are powdered, they are mixed according to the described ratio, first reflux extraction is performed with 70%-90% ethanol for 2-5 hours, the solid-liquid ratio is 1:2-1:30, the extraction is repeated 2-5 times, each extraction liquid is filtered, the filtrate is enriched, and the solvent is removed by a rotary evaporator to obtain a solvent-free ethanol extract YF-A.

5. A Chinese medicine preparation for treating liver cancer and lung cancer, wherein the effective ingredient is the Chinese medicine composition according to any one of claims 1 to 3.

6. A Chinese medicine preparation for treating liver cancer and lung cancer, wherein the active ingredient is the ethanol extract YF-A obtained by the following preparation method: after the Chinese medicinal materials described in any one of claims 1 to 3 are powdered, they are mixed according to the described ratio, first reflux extraction is performed with 70%-90% ethanol for 2-5 hours, the solid-liquid ratio is 1:2-1:30, the extraction is repeated 2-5 times, each extract is filtered, the filtrate is enriched, and the solvent is removed by a rotary evaporator to obtain a solvent-free ethanol extract YF-A.

7. A Chinese medicine preparation for treating liver cancer and lung cancer according to claim 5, characterized in that: The dosage form of the traditional Chinese medicine preparation is tablet, capsule, granule, oral liquid, spray or pill.

8. A Chinese medicine preparation for treating liver cancer and lung cancer according to claim 7, characterized in that: The preparation method of the tablet, capsule, granule, oral liquid, spray or pill comprises the following steps: (1) After the medicinal parts of the Chinese medicinal materials are powdered, they are mixed according to the ratio; first, reflux extraction is performed with 70%-90% ethanol for 2-5 hours, with a solid-liquid ratio of 1:2-1:30, and the extraction is repeated 2-5 times, and each extraction liquid is filtered, the filtrate is enriched, and the solvent is removed by a rotary evaporator to obtain a solvent-free ethanol extract YF-A; (2) evaporating the ethanol in the filter residue in (1), refluxing and extracting with distilled water for 2-5 hours, with a solid-liquid ratio of 1:2-1:30, repeating the extraction 2-5 times, filtering each extract, enriching the filtrate, and removing the solvent by rotary evaporation to obtain a solvent-free water extract YF-W; (3) Add conventional excipients for Chinese medicine preparations to the extracts obtained in (1) and (2) above, and prepare tablets, capsules, granules, oral liquids, sprays or pills according to conventional preparation steps for Chinese medicine preparations.

9. Use of a Chinese medicine composition for treating liver cancer and lung cancer as described in any one of claims 1 to 3, or an ethanol extract YF-A for treating liver cancer and lung cancer as described in claim 4, or a Chinese medicine preparation as described in any one of claims 5 or 6 in the preparation of drugs for treating lung cancer and liver cancer.

Images